SCHEMBL10154337

SCHEMBL10154337

CCCCOC(OCCCC)c1ccc(O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.52
NR5A1 Q13285 1/20 0.52
ESR1 P03372 7/20 0.51
LMNA P02545 3/20 0.51
TSHR P16473 2/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2D6 P10635 2/20 0.51
CYP2C19 P33261 2/20 0.51
MAPK1 P28482 1/20 0.51
NR1H2 P55055 1/20 0.51
RNASEL Q05823 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
SLC6A2 P23975 4/20 0.46
CHRM1 P11229 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
ALDH1A1 P00352 2/20 0.46
KDR P35968 1/20 0.46
ADORA3 P0DMS8 3/20 0.45
SLC6A3 Q01959 3/20 0.45
CHRM2 P08172 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17864870 0.90 SLC2A1 (0.41) LTA4HESR1LMNATSHRCYP1A2
SCHEMBL10584634 0.82 NPC1 (0.49) LMNATSHRCYP1A2CYP2C19SMN1; SMN2
SCHEMBL9053497 0.82 MAPT (0.39) MAPK1SMN1; SMN2MAPTDRD3
SCHEMBL12694341 0.81 LTA4H (0.36) LTA4HLMNACYP1A2CYP2D6MAPK1
SCHEMBL11251423 0.81 FAAH (0.44) TSHRCYP1A2CYP2D6CYP2C19MAPK1
SCHEMBL16328958 0.80 IDO1 (0.34) LTA4HNR5A1ESR1LMNATSHR
SCHEMBL10717745 0.80 LTA4H (0.47) LTA4HLMNATSHRCYP1A2CYP2D6
SCHEMBL5388511 0.79 ACHE (0.53) LTA4HESR1LMNATSHRCYP1A2
SCHEMBL12086375 0.79 PLA2G4B (0.36) MAPK1SMN1; SMN2ALDH1A1ACHETBXAS1
SCHEMBL12694288 0.79 IDO1 (0.37) ESR1LMNATSHRCYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807436-B1 HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF INTEZYNE TECHNOLOGIES INC (US) 2014-06-18 EP disclosed
US-20130178600-A1 POLY(ETHYLENE GLYCOL) DERIVATIVES FOR CLICK CHEMISTRY INTEZYNE TECHNOLOGIES, INC. (US) 2013-07-11 US disclosed
US-8268936-B2 Synthesis of hybrid block copolymers and uses thereof INTEZYNE TECHNOLOGIES, INC. (US) 2012-09-18 US disclosed
US-20120226050-A1 POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS INTEZYNE TECHNOLOGIES, INC. (US) 2012-09-06 US disclosed
US-8212083-B2 Use in PEGylation of biologicals; variety of terminal functional groups; made by polymerizing ethylene oxide on initiators such as N-(hydroxyalkyl) imines or N,N-bis(diphenyloxophosphino)-N-hydroxyalkylamines INTEZYNE TECHNOLOGIES, INC. (US) 2012-07-03 US disclosed
US-8207353-B2 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES, INC. (US) 2012-06-26 US disclosed
US-20110224383-A1 POLY(ETHYLENE GLYCOL) DERIVATIVES FOR METAL-FREE CLICK CHEMISTRY INTEZYNE TECHNOLOGIES, INC. (US) 2011-09-15 US disclosed
WO-2011112969-A1 POLY(ETHYLENE GLYCOL) DERIVATIVES FOR METAL-FREE CLICK CHEMISTRY INTEZYNE TECHNOLOGIES, INC. (US) 2011-09-15 WO disclosed
US-7893277-B2 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES, INC. (US) 2011-02-22 US disclosed
US-20110021718-A1 SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF INTEZYNE TECHNOLOGIES (US) 2011-01-27 US disclosed
US-20100280252-A1 POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS INTEZYNE TECHNOLOGIES (US) 2010-11-04 US disclosed
US-20100160645-A1 POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS INTEZYNE TECHNOLOGIES, INC. (US) 2010-06-24 US disclosed
US-7612153-B2 conjugate polymer drugs; endcapped polyethers; nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents INTEZYNE TECHNOLOGIES, INC. (US) 2009-11-03 US disclosed
US-7601796-B2 polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions INTEZYNE TECHNOLOGIES, INC. (US) 2009-10-13 US disclosed
US-7560588-B2 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES, INC. (US) 2009-07-14 US disclosed
US-20080207913-A1 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES (US) 2008-08-28 US disclosed
US-20080188638-A1 Heterobifunctional poly(ethyleneglycol) containing acid-labile amino protecting groups and uses thereof INTEZYNE TECHNOLOGIES (US) 2008-08-07 US disclosed
WO-2007127440-A2 HETEROFUNCTIONAL POLY(ETHYLENE GLYCOL) CONTAINING ACID-LABILE AMINO PROTECTING GROUPS AND USES THEREOF INTEZYNE TECHNOLOGIES, INC. (US) 2007-11-08 WO disclosed
WO-2007127473-A2 POLY (ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS INTEZYNE TECHNOLOGIES, INC. (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280252-A1 POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS GNE, EPRS1, ALG1 LTA4H 391/4885NR5A1 4585/4885ESR1 1069/4885
US-20100160645-A1 POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS GNE, EPRS1, ALG1 LTA4H 391/4885NR5A1 4585/4885ESR1 1069/4885
US-20080188638-A1 Heterobifunctional poly(ethyleneglycol) containing acid-labile amino protecting groups and uses thereof LNPEP, GNE, DNPEP LTA4H 846/4885NR5A1 4858/4885ESR1 2603/4885
US-20120226050-A1 POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS GNE, EPRS1, ALG1 LTA4H 391/4885NR5A1 4585/4885ESR1 1069/4885
US-20080207913-A1 Poly(ethylene glycol) containing chemically disparate endgroups GNE, EPRS1, ALG1 LTA4H 391/4885NR5A1 4585/4885ESR1 1069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.